MDGL Madrigal Pharmaceuticals, Inc.

NASDAQ
$421.99

Madrigal Pharmaceuticals, Inc. (MDGL) is expected to report earnings on February 2, 2027, before the market open. The consensus earnings estimate is $1.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.1% since its last earnings release on November 3, 2026.

Madrigal Pharmaceuticals Beat Consensus Estimates
Tuesday, November 3, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs $1.34
Rev est $468.03M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $408.50

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.